Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Go back to Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer| (NASDAQ: DARE) | Delayed: 2.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.05 | 52 Week High | $ | |||
| Open | $2.05 | 52 Week Low | $ | |||
| Day High | $2.05 | P/E | N/A | |||
| Day Low | $2.05 | EPS | $ | |||
| Volume | 411 | |||||
